Načítá se...
Reduction in pulmonary artery pressures with use of sacubitril/valsartan
Pulmonary hypertension due to left heart disease (PH-LHD) frequently complicates heart failure with reduced ejection fraction (HFrEF). Specific therapies for PH have not offered an advantage in patients with PH-LHD. The combined angiotensin receptor blocker–neprilysin inhibitor (ARNI), sacubitril/va...
Uloženo v:
| Vydáno v: | J Cardiol Cases |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Japanese College of Cardiology
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6834956/ https://ncbi.nlm.nih.gov/pubmed/31719942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jccase.2019.08.006 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|